Search
for
Sort by
Research 271–300 of 1000+
- 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond
- The circulating dihydrotestosterone/testosterone ratio is increased by gut microbial 5α-reductase activity in females
- Anti-androgenetic effect of diphlorethohydroxycarmalol on testosterone-induced hair loss by inhibiting 5α-reductase and promoting Wnt/β-catenin signaling pathway in human dermal papilla cells
- 5α Reductase Deficiency—a Rare Cause of Ambiguous Genitalia and Gender Dysphoria
- Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality
- Peripheral Neuroprotective and Immunomodulatory Effects of 5α-Reductase Inhibitors in Parkinson’s Disease Models
- Antioxidant and 5α-Reductase Inhibitory Activity of Momordica charantia Extract, and Development and Characterization of Microemulsion
- Anti-SARS-CoV-2 Action of 5α-Reductase Inhibitors May Be Mediated by Dehydroepiandrosterone. Letter.
- In silico screening of effective inhibitor of 5α-reductase type 1 for androgenic alopecia treatment
- Synthesis and Study of Some 17a-aza-D-homo Steroids as 5α-Reductase Inhibitors
- 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study
- Re: Association of Suicidality and Depression with 5α-Reductase Inhibitors
- The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male Sexual Function and Psychological Well-Being
- Improvement of Tissue Survival of Skin Flaps by 5α-Reductase Inhibitors: Possible Involvement of Nitric Oxide and Inducible Nitric Oxide Synthase
- A New Era of 5α-Reductase Inhibitors for Androgenetic Alopecia
- Genetic analysis of 5 α reductase type 2 enzyme in relation to oxidative stress in cases of androgenetic alopecia in a sample of egyptian population
- High-performance liquid chromatographic determination of the enantiomers of the benzoquinolinone LY 191704, a human type 1 5α-reductase inhibitor, in plasma
- Absence of Interaction Between 5α‐Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes
- Optimization and Characterization of TSG-Enriched Polygonum multiflorum Extract and Its Dual Mechanism Against Androgenetic Alopecia via 5α-Reductase Inhibition and Wnt/β-Catenin Activation
- 5α-reductase Inhibitors: Finasteride and Dutasteride in Feminising Therapy
- A study on the regulation of dermal papilla cells proliferation and anti-androgen mechanism of Terminalia bellirica (Gaertn.) Roxb.: Verification based on inhibition of 5α-reductase and cell model
- Sexual dysfunction associated with 5α-reductase inhibitors in the treatment of androgenetic alopecia: a systematic review
- Risks Associated with 5α-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance
- Pharmacological inhibition of 5α-reductase in androgenetic alopecia: a comparative narrative review of finasteride and dutasteride, with attention to responder heterogeneity and female pattern hair loss
- Pharmacological inhibition of 5α-reductase in androgenetic alopecia: a comparative narrative review of finasteride and dutasteride, with attention to responder heterogeneity and female pattern hair loss
- Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study
- 5α-Reductase underscores the development of pectoral fin breeding tubercles in zebrafish
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)